Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Candel Therapeutics, Inc.NASDAQ: CADL
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue remains negative
Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.
Context
- Revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 125K | +0.0% |
| FY2021 | 2021-12-31 | 125K | — |
Revenue vs competitors
How CADL compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Sep 2026 | $378.98M USD | +51.3% | — | |
| LTM Mar 2026 | $227.18M USD | -2.4% | +0.0% | |
| LTM Mar 2026 | $217.17M USD | +396.7% | — | |
| LTM Mar 2026 | $157.08M USD | +3.1% | -0.1% | |
GNLXGenelux Corporation | LTM Mar 2026 | $8K USD | — | -91.0% |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | +175.9% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥0 CNY | -100.0% | — |
| Peer median (excluding CADL) | — | +0.3% | -0.0% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 125K | 125K | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 125K | 125K | 0 | 0 | 0 |
| Gross Margin | 100.0% | 100.0% | — | — | — |
| Research & Development | 15.18M | 20.79M | 24.51M | 19.31M | 30.5M |
| Selling, General & Admin | 10.67M | 14.06M | 13.89M | 14.06M | 17.77M |
| Operating Expenses | 24.78M | 34.8M | 38.39M | 33.37M | 48.27M |
| Depreciation & Amortization | 232K | 778K | 960K | 990K | 845K |
| EBITDA | (24.42M) | (16.31M) | (34.38M) | (52.1M) | (35.22M) |
| EBITDA Margin | -19534.4% | -13046.4% | — | — | — |
| Operating Income | (24.65M) | (34.67M) | (38.39M) | (33.37M) | (48.27M) |
| Operating Margin | -19720.0% | -27739.2% | — | — | — |
| Interest Income | 0 | 1.22M | 2.08M | 1.09M | 3.92M |
| Interest Expense | 53K | 1.71M | 2.6M | 2.09M | 2.12M |
| Other Income / Expenses | (10.4M) | 15.93M | 452K | (21.81M) | 10.08M |
| Income Before Tax | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Pre-Tax Margin | -28899.2% | -15035.2% | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (36.12M) | (18.79M) | (37.94M) | (55.18M) | (38.18M) |
| Net Margin | -28899.2% | -15035.2% | — | — | — |
| EPS (Basic) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| EPS (Diluted) | (1.26) | (0.10) | (1.31) | (1.74) | (0.72) |
| Weighted Avg Shares | 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
| Weighted Avg Shares (Diluted) | 28.69M | 28.82M | 28.94M | 31.68M | 52.96M |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.